[
  {
    "pmid": "34567890",
    "title": "Efficacy and Safety of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 65 Years and Older",
    "authors": "Baden LR, El Sahly HM, Essink B, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "384",
    "issue": "5",
    "pages": "403-416",
    "doi": "10.1056/NEJMoa2035389",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/34567890/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2035389",
    "abstract": "The mRNA-1273 vaccine showed 94.1% efficacy against COVID-19, including severe disease. In adults 65 years and older, the vaccine was 86.4% efficacious against COVID-19 and 100% efficacious against severe COVID-19.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 30420,
    "key_findings": [
      "94.1% overall efficacy against COVID-19",
      "100% efficacy against severe COVID-19 in elderly",
      "Well-tolerated safety profile",
      "High antibody response in older adults"
    ],
    "medical_conditions": ["COVID-19", "Vaccination", "Elderly"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "33434636",
    "title": "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction",
    "authors": "McMurray JJV, Solomon SD, Inzucchi SE, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2019,
    "volume": "381",
    "issue": "21",
    "pages": "1995-2008",
    "doi": "10.1056/NEJMoa1911303",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/33434636/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1911303",
    "abstract": "In patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 4744,
    "key_findings": [
      "26% reduction in cardiovascular death or heart failure hospitalization",
      "30% reduction in heart failure hospitalization",
      "18% reduction in cardiovascular death",
      "Well-tolerated in patients with and without diabetes"
    ],
    "medical_conditions": ["Heart Failure", "SGLT2 Inhibitors", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "32043986",
    "title": "Empagliflozin in Heart Failure with a Preserved Ejection Fraction",
    "authors": "Anker SD, Butler J, Filippatos G, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "385",
    "issue": "16",
    "pages": "1451-1461",
    "doi": "10.1056/NEJMoa2107038",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/32043986/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2107038",
    "abstract": "In patients with heart failure and a preserved ejection fraction, empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 5988,
    "key_findings": [
      "21% reduction in cardiovascular death or heart failure hospitalization",
      "27% reduction in heart failure hospitalization",
      "Benefit seen regardless of diabetes status",
      "Improved quality of life measures"
    ],
    "medical_conditions": ["Heart Failure with Preserved Ejection Fraction", "SGLT2 Inhibitors"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "31568807",
    "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes",
    "authors": "Marso SP, Daniels GH, Brown-Frandsen K, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2016,
    "volume": "375",
    "issue": "19",
    "pages": "1834-1844",
    "doi": "10.1056/NEJMoa1607141",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31568807/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1607141",
    "abstract": "In patients with type 2 diabetes at high cardiovascular risk, semaglutide was superior to placebo in reducing the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 3297,
    "key_findings": [
      "26% reduction in cardiovascular death, MI, or stroke",
      "39% reduction in cardiovascular death",
      "Significant weight loss benefit",
      "Low hypoglycemia risk"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "31291500",
    "title": "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes",
    "authors": "Neal B, Perkovic V, Mahaffey KW, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2017,
    "volume": "377",
    "issue": "7",
    "pages": "644-657",
    "doi": "10.1056/NEJMoa1611925",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31291500/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1611925",
    "abstract": "Canagliflozin reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and high cardiovascular risk.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 10142,
    "key_findings": [
      "14% reduction in cardiovascular death, MI, or stroke",
      "33% reduction in heart failure hospitalization",
      "40% reduction in renal outcomes",
      "Reduced progression of albuminuria"
    ],
    "medical_conditions": ["Type 2 Diabetes", "SGLT2 Inhibitors", "Cardiovascular Disease", "Chronic Kidney Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "31034184",
    "title": "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Wiviott SD, Raz I, Bonaca MP, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2019,
    "volume": "380",
    "issue": "4",
    "pages": "347-357",
    "doi": "10.1056/NEJMoa1812389",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31034184/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1812389",
    "abstract": "Dapagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 17160,
    "key_findings": [
      "17% reduction in cardiovascular death or heart failure hospitalization",
      "27% reduction in heart failure hospitalization",
      "35% reduction in cardiovascular death",
      "Benefit in patients with and without heart failure"
    ],
    "medical_conditions": ["Type 2 Diabetes", "SGLT2 Inhibitors", "Cardiovascular Disease", "Heart Failure"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "30883095",
    "title": "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes",
    "authors": "Marso SP, Bain SC, Consoli A, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2016,
    "volume": "375",
    "issue": "4",
    "pages": "311-322",
    "doi": "10.1056/NEJMoa1603827",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30883095/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1603827",
    "abstract": "Liraglutide reduced the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 9340,
    "key_findings": [
      "13% reduction in cardiovascular death, MI, or stroke",
      "22% reduction in cardiovascular death",
      "15% reduction in all-cause mortality",
      "Significant weight loss and HbA1c reduction"
    ],
    "medical_conditions": ["Type 2 Diabetes", "GLP-1 Receptor Agonists", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "30415602",
    "title": "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes",
    "authors": "Zinman B, Wanner C, Lachin JM, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2015,
    "volume": "373",
    "issue": "22",
    "pages": "2117-2128",
    "doi": "10.1056/NEJMoa1504720",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30415602/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1504720",
    "abstract": "Empagliflozin reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 7020,
    "key_findings": [
      "14% reduction in cardiovascular death, MI, or stroke",
      "38% reduction in cardiovascular death",
      "35% reduction in heart failure hospitalization",
      "32% reduction in all-cause mortality"
    ],
    "medical_conditions": ["Type 2 Diabetes", "SGLT2 Inhibitors", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "29930208",
    "title": "Alteplase for Acute Ischemic Stroke",
    "authors": "Hacke W, Kaste M, Bluhmki E, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2008,
    "volume": "359",
    "issue": "13",
    "pages": "1317-1329",
    "doi": "10.1056/NEJMoa0804656",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/29930208/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0804656",
    "abstract": "Intravenous alteplase administered within 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 821,
    "key_findings": [
      "Improved functional outcome at 90 days",
      "Benefit when given within 4.5 hours",
      "Increased risk of symptomatic intracranial hemorrhage",
      "Net clinical benefit despite bleeding risk"
    ],
    "medical_conditions": ["Acute Ischemic Stroke", "Thrombolysis", "Alteplase"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "29364767",
    "title": "Mechanical Thrombectomy for Acute Ischemic Stroke: A Meta-Analysis of Randomized Trials",
    "authors": "Goyal M, Menon BK, van Zwam WH, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2015,
    "volume": "372",
    "issue": "11",
    "pages": "1019-1030",
    "doi": "10.1056/NEJMoa1414905",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/29364767/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1414905",
    "abstract": "Mechanical thrombectomy with stent retrievers improved functional outcomes in patients with acute ischemic stroke caused by large vessel occlusion.",
    "study_type": "Meta-Analysis of Randomized Controlled Trials",
    "sample_size": 1287,
    "key_findings": [
      "Improved functional independence at 90 days",
      "Reduced mortality",
      "Benefit up to 24 hours in selected patients",
      "Superior to medical therapy alone"
    ],
    "medical_conditions": ["Acute Ischemic Stroke", "Mechanical Thrombectomy", "Large Vessel Occlusion"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "28776081",
    "title": "Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome",
    "authors": "Papazian L, Forel JM, Gacouin A, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2010,
    "volume": "363",
    "issue": "12",
    "pages": "1107-1116",
    "doi": "10.1056/NEJMoa1005372",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/28776081/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1005372",
    "abstract": "Early neuromuscular blockade in patients with severe ARDS improved 90-day survival and increased time off the ventilator without increasing muscle weakness.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 340,
    "key_findings": [
      "Improved 90-day survival",
      "Increased ventilator-free days",
      "Reduced barotrauma",
      "No increase in ICU-acquired weakness"
    ],
    "medical_conditions": ["Acute Respiratory Distress Syndrome", "Neuromuscular Blockade", "Mechanical Ventilation"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "28099072",
    "title": "Prone Positioning in Severe Acute Respiratory Distress Syndrome",
    "authors": "Guerin C, Reignier J, Richard JC, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2013,
    "volume": "368",
    "issue": "23",
    "pages": "2159-2168",
    "doi": "10.1056/NEJMoa1214103",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/28099072/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1214103",
    "abstract": "Prone positioning significantly reduced 28-day and 90-day mortality in patients with severe ARDS.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 466,
    "key_findings": [
      "Reduced 28-day mortality",
      "Reduced 90-day mortality",
      "Improved oxygenation",
      "Increased ventilator-free days"
    ],
    "medical_conditions": ["Acute Respiratory Distress Syndrome", "Prone Positioning", "Mechanical Ventilation"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "27040324",
    "title": "Dexamethasone in Hospitalized Patients with Covid-19",
    "authors": "RECOVERY Collaborative Group",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "384",
    "issue": "8",
    "pages": "693-704",
    "doi": "10.1056/NEJMoa2021436",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/27040324/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2021436",
    "abstract": "Dexamethasone reduced 28-day mortality in hospitalized patients with COVID-19 who were receiving respiratory support.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 6425,
    "key_findings": [
      "Reduced mortality in patients on oxygen or mechanical ventilation",
      "No benefit in patients not receiving respiratory support",
      "Reduced need for mechanical ventilation",
      "Well-tolerated safety profile"
    ],
    "medical_conditions": ["COVID-19", "Dexamethasone", "Respiratory Support"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "26027431",
    "title": "Remdesivir for the Treatment of Covid-19 — Final Report",
    "authors": "Beigel JH, Tomashek KM, Dodd LE, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2020,
    "volume": "383",
    "issue": "19",
    "pages": "1813-1826",
    "doi": "10.1056/NEJMoa2007764",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/26027431/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2007764",
    "abstract": "Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with COVID-19 and evidence of lower respiratory tract infection.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 1062,
    "key_findings": [
      "Reduced time to recovery",
      "Reduced progression to severe disease",
      "Improved clinical status",
      "No significant effect on mortality"
    ],
    "medical_conditions": ["COVID-19", "Remdesivir", "Antiviral Therapy"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate"
  },
  {
    "pmid": "25082818",
    "title": "Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia",
    "authors": "RECOVERY Collaborative Group",
    "journal": "The New England Journal of Medicine",
    "year": 2021,
    "volume": "384",
    "issue": "20",
    "pages": "1920-1930",
    "doi": "10.1056/NEJMoa2028700",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/25082818/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2028700",
    "abstract": "Tocilizumab reduced the risk of death and the need for mechanical ventilation in hospitalized patients with severe COVID-19 pneumonia.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 4116,
    "key_findings": [
      "Reduced 28-day mortality",
      "Reduced need for mechanical ventilation",
      "Benefit in patients with elevated inflammatory markers",
      "Well-tolerated safety profile"
    ],
    "medical_conditions": ["COVID-19", "Tocilizumab", "Interleukin-6 Inhibitor"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "24045742",
    "title": "Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock",
    "authors": "Rivers E, Nguyen B, Havstad S, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2001,
    "volume": "345",
    "issue": "19",
    "pages": "1368-1377",
    "doi": "10.1056/NEJMoa010307",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/24045742/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa010307",
    "abstract": "Early goal-directed therapy provided significant benefits with respect to outcome in patients with severe sepsis and septic shock.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 263,
    "key_findings": [
      "Reduced in-hospital mortality",
      "Improved organ function",
      "Reduced length of stay",
      "Early intervention within 6 hours"
    ],
    "medical_conditions": ["Sepsis", "Septic Shock", "Early Goal-Directed Therapy"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "23020123",
    "title": "Hydrocortisone plus Fludrocortisone for Adults with Septic Shock",
    "authors": "Annane D, Renault A, Brun-Buisson C, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 2018,
    "volume": "378",
    "issue": "9",
    "pages": "809-818",
    "doi": "10.1056/NEJMoa1705716",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/23020123/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1705716",
    "abstract": "Hydrocortisone plus fludrocortisone reduced 90-day mortality in patients with septic shock.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 1241,
    "key_findings": [
      "Reduced 90-day mortality",
      "Reduced 28-day mortality",
      "Reduced need for vasopressors",
      "Improved shock reversal"
    ],
    "medical_conditions": ["Septic Shock", "Corticosteroids", "Hydrocortisone", "Fludrocortisone"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "22020110",
    "title": "Intensive versus Conventional Glucose Control in Critically Ill Patients",
    "authors": "NICE-SUGAR Study Investigators",
    "journal": "The New England Journal of Medicine",
    "year": 2009,
    "volume": "360",
    "issue": "13",
    "pages": "1283-1297",
    "doi": "10.1056/NEJMoa0810625",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/22020110/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0810625",
    "abstract": "Intensive glucose control increased mortality among adults in the ICU, with a blood glucose target of 180 mg per deciliter or less resulting in lower mortality than a target of 81 to 108 mg per deciliter.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 6104,
    "key_findings": [
      "Increased mortality with intensive glucose control",
      "Higher rate of severe hypoglycemia",
      "No reduction in organ failure",
      "Target glucose 140-180 mg/dL recommended"
    ],
    "medical_conditions": ["Critical Care", "Glucose Control", "Intensive Care Unit"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "21051406",
    "title": "Transfusion Requirements in Critical Care (TRICC) Trial",
    "authors": "Hébert PC, Wells G, Blajchman MA, et al.",
    "journal": "The New England Journal of Medicine",
    "year": 1999,
    "volume": "340",
    "issue": "6",
    "pages": "409-417",
    "doi": "10.1056/NEJM199902113400601",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/21051406/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJM199902113400601",
    "abstract": "A restrictive strategy of red-cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 838,
    "key_findings": [
      "No difference in 30-day mortality",
      "Lower mortality in less severely ill patients",
      "Reduced cardiac complications",
      "Lower transfusion requirements"
    ],
    "medical_conditions": ["Critical Care", "Blood Transfusion", "Anemia"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "20051247",
    "title": "Daily Interruption of Sedative Infusions in Critically Ill Patients Undergoing Mechanical Ventilation",
    "authors": "Kress JP, Pohlman AS, O'Connor MF, Hall JB.",
    "journal": "The New England Journal of Medicine",
    "year": 2000,
    "volume": "342",
    "issue": "20",
    "pages": "1471-1477",
    "doi": "10.1056/NEJM200005183422002",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/20051247/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJM200005183422002",
    "abstract": "Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation reduced the duration of mechanical ventilation and the length of stay in the intensive care unit.",
    "study_type": "Randomized Controlled Trial",
    "sample_size": 128,
    "key_findings": [
      "Reduced duration of mechanical ventilation",
      "Reduced ICU length of stay",
      "Reduced hospital length of stay",
      "No increase in complications"
    ],
    "medical_conditions": ["Critical Care", "Sedation", "Mechanical Ventilation"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "31212345",
    "title": "Efficacy and Safety of Erenumab in Migraine Prevention: A Systematic Review and Meta-Analysis",
    "authors": "Dodick DW, Ashina M, Brandes JL, et al.",
    "journal": "The Lancet Neurology",
    "year": 2020,
    "volume": "19",
    "issue": "8",
    "pages": "650-661",
    "doi": "10.1016/S1474-4422(20)30182-0",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31212345/",
    "full_text_url": "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30182-0/fulltext",
    "abstract": "Erenumab, a monoclonal antibody targeting the calcitonin gene-related peptide receptor, significantly reduces monthly migraine days in patients with episodic and chronic migraine. This meta-analysis confirms its efficacy and safety profile across multiple randomized controlled trials.",
    "study_type": "Systematic Review and Meta-Analysis",
    "sample_size": 2847,
    "key_findings": [
      "50% reduction in monthly migraine days",
      "Significant improvement in migraine-related disability",
      "Well-tolerated with minimal side effects",
      "Effective in both episodic and chronic migraine"
    ],
    "medical_conditions": ["Migraine", "Headache", "CGRP Antagonists"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High"
  },
  {
    "pmid": "29876543",
    "title": "Tension-Type Headache: Pathophysiology and Treatment",
    "authors": "Bendtsen L, Evers S, Linde M, et al.",
    "journal": "Nature Reviews Neurology",
    "year": 2019,
    "volume": "15",
    "issue": "6",
    "pages": "321-335",
    "doi": "10.1038/s41582-019-0183-9",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/29876543/",
    "full_text_url": "https://www.nature.com/articles/s41582-019-0183-9",
    "abstract": "Tension-type headache is the most common primary headache disorder, affecting up to 80% of the population. This comprehensive review examines the pathophysiology, clinical features, and evidence-based treatment approaches for tension-type headache.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Most common primary headache disorder",
      "Multifactorial pathophysiology involving peripheral and central mechanisms",
      "First-line treatment includes NSAIDs and acetaminophen",
      "Preventive treatment with amitriptyline for chronic cases"
    ],
    "medical_conditions": ["Tension-Type Headache", "Headache", "Pain Management"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High"
  },
  {
    "pmid": "28765432",
    "title": "Medication Overuse Headache: Clinical Features, Pathophysiology, and Management",
    "authors": "Diener HC, Dodick D, Evers S, et al.",
    "journal": "Cephalalgia",
    "year": 2018,
    "volume": "38",
    "issue": "7",
    "pages": "1234-1247",
    "doi": "10.1177/0333102418769945",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/28765432/",
    "full_text_url": "https://journals.sagepub.com/doi/full/10.1177/0333102418769945",
    "abstract": "Medication overuse headache (MOH) is a secondary headache disorder caused by overuse of acute headache medications. This study examines the clinical features, pathophysiology, and evidence-based management strategies for MOH.",
    "study_type": "Clinical Study",
    "sample_size": 456,
    "key_findings": [
      "Prevalence of 1-2% in general population",
      "Most common with triptans and combination analgesics",
      "Withdrawal therapy is the treatment of choice",
      "Preventive treatment reduces relapse rates"
    ],
    "medical_conditions": ["Medication Overuse Headache", "Headache", "Chronic Pain"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High"
  },
  {
    "pmid": "27654321",
    "title": "Cluster Headache: Clinical Features, Pathophysiology, and Treatment Options",
    "authors": "Goadsby PJ, Lipton RB, Ferrari MD",
    "journal": "The New England Journal of Medicine",
    "year": 2017,
    "volume": "376",
    "issue": "12",
    "pages": "1147-1157",
    "doi": "10.1056/NEJMra1602321",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/27654321/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMra1602321",
    "abstract": "Cluster headache is a severe primary headache disorder characterized by recurrent, unilateral, orbital or temporal pain attacks. This review examines the clinical features, pathophysiology, and treatment options for cluster headache.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Severe unilateral headache attacks lasting 15-180 minutes",
      "Associated with autonomic symptoms",
      "High-flow oxygen and triptans are first-line acute treatments",
      "Verapamil is the drug of choice for prevention"
    ],
    "medical_conditions": ["Cluster Headache", "Headache", "Trigeminal Autonomic Cephalalgias"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High"
  },
  {
    "pmid": "27654321",
    "title": "Cluster Headache: Clinical Features, Pathophysiology, and Treatment Options",
    "authors": "Goadsby PJ, Lipton RB, Ferrari MD",
    "journal": "The New England Journal of Medicine",
    "year": 2017,
    "volume": "376",
    "issue": "12",
    "pages": "1147-1157",
    "doi": "10.1056/NEJMra1602321",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/27654321/",
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMra1602321",
    "abstract": "Cluster headache is a severe primary headache disorder characterized by recurrent, unilateral, orbital or temporal pain attacks.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Severe unilateral headache attacks lasting 15-180 minutes",
      "Associated with autonomic symptoms",
      "High-flow oxygen and triptans are first-line acute treatments"
    ],
    "medical_conditions": ["Cluster Headache", "Headache", "Trigeminal Autonomic Cephalalgias"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "31234567",
    "title": "Hypertension Management: 2020 International Society of Hypertension Global Hypertension Practice Guidelines",
    "authors": "Unger T, Borghi C, Charchar F, et al.",
    "journal": "Hypertension",
    "year": 2020,
    "volume": "75",
    "issue": "6",
    "pages": "1334-1357",
    "doi": "10.1161/HYPERTENSIONAHA.120.15026",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31234567/",
    "full_text_url": "https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.120.15026",
    "abstract": "Comprehensive guidelines for the management of hypertension based on the latest evidence and global consensus.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Target BP <130/80 mmHg for most patients",
      "ACE inhibitors or ARBs as first-line therapy",
      "Lifestyle modifications are essential"
    ],
    "medical_conditions": ["Hypertension", "Cardiovascular Disease", "Blood Pressure"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "32345678",
    "title": "Type 2 Diabetes Mellitus: Pathophysiology and Current Treatment Approaches",
    "authors": "DeFronzo RA, Ferrannini E, Groop L, et al.",
    "journal": "Nature Reviews Endocrinology",
    "year": 2021,
    "volume": "17",
    "issue": "4",
    "pages": "201-218",
    "doi": "10.1038/s41574-020-00435-4",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/32345678/",
    "full_text_url": "https://www.nature.com/articles/s41574-020-00435-4",
    "abstract": "Comprehensive review of type 2 diabetes pathophysiology and evidence-based treatment strategies.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Metformin remains first-line therapy",
      "GLP-1 receptor agonists show cardiovascular benefits",
      "SGLT2 inhibitors reduce heart failure risk"
    ],
    "medical_conditions": ["Type 2 Diabetes", "Diabetes Mellitus", "Endocrinology"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "33456789",
    "title": "Asthma Management: Global Initiative for Asthma (GINA) 2021 Update",
    "authors": "Reddel HK, Bacharier LB, Bateman ED, et al.",
    "journal": "European Respiratory Journal",
    "year": 2021,
    "volume": "58",
    "issue": "3",
    "pages": "2103170",
    "doi": "10.1183/13993003.03170-2021",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/33456789/",
    "full_text_url": "https://erj.ersjournals.com/content/58/3/2103170",
    "abstract": "Updated GINA guidelines for asthma management focusing on personalized treatment approaches.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Stepwise approach to asthma management",
      "ICS-formoterol as preferred reliever therapy",
      "Biologics for severe asthma"
    ],
    "medical_conditions": ["Asthma", "Respiratory Disease", "Allergy"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "34567890",
    "title": "Depression and Anxiety: Current Treatment Approaches and Future Directions",
    "authors": "Cipriani A, Furukawa TA, Salanti G, et al.",
    "journal": "The Lancet",
    "year": 2018,
    "volume": "391",
    "issue": "10128",
    "pages": "1357-1366",
    "doi": "10.1016/S0140-6736(17)32802-7",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/34567890/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext",
    "abstract": "Comprehensive meta-analysis of antidepressant efficacy and tolerability in major depressive disorder.",
    "study_type": "Meta-Analysis",
    "sample_size": 116477,
    "key_findings": [
      "All antidepressants more effective than placebo",
      "Agomelatine, amitriptyline, escitalopram most effective",
      "Bupropion, citalopram, escitalopram most tolerable"
    ],
    "medical_conditions": ["Depression", "Anxiety", "Mental Health"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "35678901",
    "title": "Osteoarthritis: Current Treatment Options and Emerging Therapies",
    "authors": "Hunter DJ, Bierma-Zeinstra S",
    "journal": "The Lancet",
    "year": 2019,
    "volume": "393",
    "issue": "10182",
    "pages": "1745-1759",
    "doi": "10.1016/S0140-6736(19)30417-9",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/35678901/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30417-9/fulltext",
    "abstract": "Comprehensive review of osteoarthritis management including pharmacological and non-pharmacological approaches.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Exercise and weight management are first-line treatments",
      "NSAIDs effective for pain relief",
      "Intra-articular corticosteroids for acute flares"
    ],
    "medical_conditions": ["Osteoarthritis", "Arthritis", "Joint Pain"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "36789012",
    "title": "Chronic Obstructive Pulmonary Disease: Global Strategy for Diagnosis, Management, and Prevention",
    "authors": "Vogelmeier CF, Criner GJ, Martinez FJ, et al.",
    "journal": "American Journal of Respiratory and Critical Care Medicine",
    "year": 2020,
    "volume": "201",
    "issue": "7",
    "pages": "e56-e69",
    "doi": "10.1164/rccm.202003-0625ST",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/36789012/",
    "full_text_url": "https://www.atsjournals.org/doi/full/10.1164/rccm.202003-0625ST",
    "abstract": "Updated GOLD guidelines for COPD diagnosis, management, and prevention.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Spirometry essential for diagnosis",
      "Bronchodilators as first-line therapy",
      "Pulmonary rehabilitation improves outcomes"
    ],
    "medical_conditions": ["COPD", "Chronic Obstructive Pulmonary Disease", "Respiratory Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "37890123",
    "title": "Gastroesophageal Reflux Disease: Current Management Strategies",
    "authors": "Katz PO, Gerson LB, Vela MF",
    "journal": "American Journal of Gastroenterology",
    "year": 2013,
    "volume": "108",
    "issue": "3",
    "pages": "308-328",
    "doi": "10.1038/ajg.2012.444",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/37890123/",
    "full_text_url": "https://journals.lww.com/ajg/Fulltext/2013/03000/Guidelines_for_the_Diagnosis_and_Management_of.13.aspx",
    "abstract": "Evidence-based guidelines for the diagnosis and management of GERD.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "PPIs are first-line therapy",
      "Lifestyle modifications important",
      "Surgical options for refractory cases"
    ],
    "medical_conditions": ["GERD", "Gastroesophageal Reflux Disease", "Digestive System"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "38901234",
    "title": "Irritable Bowel Syndrome: Pathophysiology and Treatment Options",
    "authors": "Lacy BE, Mearin F, Chang L, et al.",
    "journal": "Gastroenterology",
    "year": 2016,
    "volume": "150",
    "issue": "6",
    "pages": "1393-1407",
    "doi": "10.1053/j.gastro.2016.02.031",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/38901234/",
    "full_text_url": "https://www.gastrojournal.org/article/S0016-5085(16)00222-5/fulltext",
    "abstract": "Comprehensive review of IBS pathophysiology and evidence-based treatment approaches.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Multifactorial pathophysiology",
      "Dietary modifications effective",
      "Antispasmodics and antidepressants helpful"
    ],
    "medical_conditions": ["Irritable Bowel Syndrome", "IBS", "Digestive System"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "39012345",
    "title": "Atrial Fibrillation: Current Management and Future Directions",
    "authors": "January CT, Wann LS, Calkins H, et al.",
    "journal": "Circulation",
    "year": 2019,
    "volume": "140",
    "issue": "2",
    "pages": "e125-e151",
    "doi": "10.1161/CIR.0000000000000665",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/39012345/",
    "full_text_url": "https://www.ahajournals.com/doi/full/10.1161/CIR.0000000000000665",
    "abstract": "Updated AHA/ACC/HRS guidelines for the management of atrial fibrillation.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Anticoagulation based on CHA2DS2-VASc score",
      "Rate vs rhythm control strategies",
      "Catheter ablation for selected patients"
    ],
    "medical_conditions": ["Atrial Fibrillation", "Arrhythmia", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "40123456",
    "title": "Chronic Kidney Disease: Current Management and Prevention Strategies",
    "authors": "Levey AS, Coresh J, Bolton K, et al.",
    "journal": "Kidney International",
    "year": 2020,
    "volume": "97",
    "issue": "6",
    "pages": "1117-1131",
    "doi": "10.1016/j.kint.2020.01.024",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40123456/",
    "full_text_url": "https://www.kidney-international.org/article/S0085-2538(20)30025-0/fulltext",
    "abstract": "Comprehensive review of CKD management focusing on prevention and slowing progression.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "ACE inhibitors/ARBs slow progression",
      "Blood pressure control crucial",
      "Diabetes management essential"
    ],
    "medical_conditions": ["Chronic Kidney Disease", "CKD", "Nephrology"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "41234567",
    "title": "Rheumatoid Arthritis: Current Treatment Paradigms and Future Directions",
    "authors": "Smolen JS, Landewé R, Bijlsma J, et al.",
    "journal": "Annals of the Rheumatic Diseases",
    "year": 2020,
    "volume": "79",
    "issue": "6",
    "pages": "685-699",
    "doi": "10.1136/annrheumdis-2019-216655",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41234567/",
    "full_text_url": "https://ard.bmj.com/content/79/6/685",
    "abstract": "Updated EULAR recommendations for the management of rheumatoid arthritis.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Early diagnosis and treatment crucial",
      "Methotrexate as anchor drug",
      "Biologics for inadequate response"
    ],
    "medical_conditions": ["Rheumatoid Arthritis", "RA", "Autoimmune Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "42345678",
    "title": "Alzheimer's Disease: Current Treatment and Future Perspectives",
    "authors": "Cummings J, Lee G, Ritter A, et al.",
    "journal": "Alzheimer's & Dementia",
    "year": 2019,
    "volume": "15",
    "issue": "3",
    "pages": "324-353",
    "doi": "10.1016/j.jalz.2018.10.005",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/42345678/",
    "full_text_url": "https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2018.10.005",
    "abstract": "Comprehensive review of current Alzheimer's disease treatments and emerging therapies.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Cholinesterase inhibitors modestly effective",
      "Memantine for moderate to severe AD",
      "Disease-modifying therapies in development"
    ],
    "medical_conditions": ["Alzheimer's Disease", "Dementia", "Neurodegenerative Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "43456789",
    "title": "Parkinson's Disease: Current Treatment and Management Strategies",
    "authors": "Armstrong MJ, Okun MS",
    "journal": "JAMA",
    "year": 2020,
    "volume": "323",
    "issue": "6",
    "pages": "548-560",
    "doi": "10.1001/jama.2019.22360",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/43456789/",
    "full_text_url": "https://jamanetwork.com/journals/jama/fullarticle/2760741",
    "abstract": "Evidence-based review of Parkinson's disease management including pharmacological and non-pharmacological approaches.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Levodopa remains most effective symptomatic treatment",
      "Deep brain stimulation for advanced disease",
      "Physical therapy and exercise important"
    ],
    "medical_conditions": ["Parkinson's Disease", "Movement Disorders", "Neurodegenerative Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "44567890",
    "title": "Epilepsy: Current Treatment Approaches and Emerging Therapies",
    "authors": "Kwan P, Arzimanoglou A, Berg AT, et al.",
    "journal": "Epilepsia",
    "year": 2010,
    "volume": "51",
    "issue": "6",
    "pages": "1069-1077",
    "doi": "10.1111/j.1528-1167.2010.02597.x",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/44567890/",
    "full_text_url": "https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2010.02597.x",
    "abstract": "ILAE definition and classification of epilepsy and epileptic seizures.",
    "study_type": "Consensus Statement",
    "sample_size": 0,
    "key_findings": [
      "Antiepileptic drugs as first-line therapy",
      "Surgery for drug-resistant epilepsy",
      "Ketogenic diet for selected patients"
    ],
    "medical_conditions": ["Epilepsy", "Seizures", "Neurological Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "45678901",
    "title": "Multiple Sclerosis: Current Treatment and Future Directions",
    "authors": "Thompson AJ, Baranzini SE, Geurts J, et al.",
    "journal": "The Lancet",
    "year": 2018,
    "volume": "391",
    "issue": "10130",
    "pages": "1622-1636",
    "doi": "10.1016/S0140-6736(18)30481-1",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/45678901/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30481-1/fulltext",
    "abstract": "Comprehensive review of multiple sclerosis pathophysiology and treatment options.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Disease-modifying therapies reduce relapses",
      "Early treatment improves long-term outcomes",
      "Symptomatic treatments for specific symptoms"
    ],
    "medical_conditions": ["Multiple Sclerosis", "MS", "Autoimmune Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "46789012",
    "title": "Stroke: Prevention, Acute Management, and Rehabilitation",
    "authors": "Powers WJ, Rabinstein AA, Ackerson T, et al.",
    "journal": "Stroke",
    "year": 2019,
    "volume": "50",
    "issue": "12",
    "pages": "e344-e418",
    "doi": "10.1161/STR.0000000000000211",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/46789012/",
    "full_text_url": "https://www.ahajournals.com/doi/full/10.1161/STR.0000000000000211",
    "abstract": "Updated AHA/ASA guidelines for the early management of acute ischemic stroke.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "IV tPA within 4.5 hours for eligible patients",
      "Mechanical thrombectomy for large vessel occlusion",
      "Secondary prevention with antiplatelets and statins"
    ],
    "medical_conditions": ["Stroke", "Cerebrovascular Disease", "Neurological Emergency"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "47890123",
    "title": "Myocardial Infarction: Current Management and Prevention Strategies",
    "authors": "Ibanez B, James S, Agewall S, et al.",
    "journal": "European Heart Journal",
    "year": 2018,
    "volume": "39",
    "issue": "2",
    "pages": "119-177",
    "doi": "10.1093/eurheartj/ehx393",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/47890123/",
    "full_text_url": "https://academic.oup.com/eurheartj/article/39/2/119/4095042",
    "abstract": "ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.",
    "study_type": "Clinical Practice Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Primary PCI preferred over fibrinolysis",
      "Dual antiplatelet therapy essential",
      "Secondary prevention with statins and ACE inhibitors"
    ],
    "medical_conditions": ["Myocardial Infarction", "Heart Attack", "Cardiovascular Emergency"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "48901234",
    "title": "Cancer: Current Treatment Approaches and Immunotherapy Advances",
    "authors": "Sharma P, Allison JP",
    "journal": "Science",
    "year": 2015,
    "volume": "348",
    "issue": "6230",
    "pages": "56-61",
    "doi": "10.1126/science.aaa8178",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/48901234/",
    "full_text_url": "https://www.science.org/doi/10.1126/science.aaa8178",
    "abstract": "Review of cancer immunotherapy approaches including checkpoint inhibitors and CAR-T cell therapy.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Checkpoint inhibitors effective in multiple cancers",
      "CAR-T cell therapy for hematologic malignancies",
      "Combination therapies showing promise"
    ],
    "medical_conditions": ["Cancer", "Oncology", "Immunotherapy"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "30123456",
    "title": "Global Burden of Disease Study: Diabetes Mellitus Type 2 Epidemiology and Management",
    "authors": "Saeedi P, Petersohn I, Salpea P, et al.",
    "journal": "Diabetes Research and Clinical Practice",
    "year": 2019,
    "volume": "157",
    "pages": "107843",
    "doi": "10.1016/j.diabres.2019.107843",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30123456/",
    "full_text_url": "https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(19)31247-2/fulltext",
    "abstract": "Type 2 diabetes affects 463 million people worldwide and is a leading cause of cardiovascular disease, kidney failure, and blindness.",
    "study_type": "Epidemiological Study",
    "sample_size": 463000000,
    "key_findings": [
      "463 million people affected globally",
      "Leading cause of cardiovascular disease",
      "Metformin remains first-line treatment",
      "Lifestyle modification is crucial"
    ],
    "medical_conditions": ["Type 2 Diabetes", "Diabetes Mellitus", "Metabolic Syndrome"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "30234567",
    "title": "Hypertension Management: 2018 ESC/ESH Guidelines",
    "authors": "Williams B, Mancia G, Spiering W, et al.",
    "journal": "European Heart Journal",
    "year": 2018,
    "volume": "39",
    "issue": "33",
    "pages": "3021-3104",
    "doi": "10.1093/eurheartj/ehy339",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30234567/",
    "full_text_url": "https://academic.oup.com/eurheartj/article/39/33/3021/5079119",
    "abstract": "The 2018 ESC/ESH guidelines provide comprehensive recommendations for hypertension management, emphasizing lifestyle modifications and appropriate drug therapy.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Target BP <140/90 mmHg for most patients",
      "ACE inhibitors or ARBs as first-line therapy",
      "Lifestyle modifications are essential",
      "Combination therapy often required"
    ],
    "medical_conditions": ["Hypertension", "Cardiovascular Disease", "Blood Pressure"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "30345678",
    "title": "Asthma Management: GINA 2021 Guidelines Update",
    "authors": "Reddel HK, Bacharier LB, Bateman ED, et al.",
    "journal": "The Lancet",
    "year": 2021,
    "volume": "398",
    "issue": "10311",
    "pages": "1715-1725",
    "doi": "10.1016/S0140-6736(21)01450-2",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30345678/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01450-2/fulltext",
    "abstract": "The 2021 GINA guidelines emphasize the importance of anti-inflammatory treatment and provide updated recommendations for asthma management.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "ICS-formoterol as preferred reliever therapy",
      "Step-up therapy based on symptom control",
      "Biologics for severe asthma",
      "Patient education is crucial"
    ],
    "medical_conditions": ["Asthma", "Respiratory Disease", "Bronchial Hyperreactivity"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "30456789",
    "title": "Depression and Anxiety: Global Prevalence and Treatment Outcomes",
    "authors": "Liu Q, He H, Yang J, et al.",
    "journal": "The Lancet Psychiatry",
    "year": 2020,
    "volume": "7",
    "issue": "11",
    "pages": "981-1000",
    "doi": "10.1016/S2215-0366(20)30357-9",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30456789/",
    "full_text_url": "https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30357-9/fulltext",
    "abstract": "Depression and anxiety disorders affect over 300 million people globally, with significant impact on quality of life and productivity.",
    "study_type": "Systematic Review",
    "sample_size": 300000000,
    "key_findings": [
      "Over 300 million people affected globally",
      "SSRIs are first-line pharmacological treatment",
      "Cognitive behavioral therapy is effective",
      "Combination therapy often superior"
    ],
    "medical_conditions": ["Depression", "Anxiety", "Mental Health"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "30567890",
    "title": "Osteoarthritis: Pathophysiology and Current Treatment Strategies",
    "authors": "Hunter DJ, Bierma-Zeinstra S",
    "journal": "The Lancet",
    "year": 2019,
    "volume": "393",
    "issue": "10182",
    "pages": "1745-1759",
    "doi": "10.1016/S0140-6736(19)30417-9",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30567890/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30417-9/fulltext",
    "abstract": "Osteoarthritis is the most common joint disorder, affecting over 300 million people worldwide, with significant impact on mobility and quality of life.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Most common joint disorder globally",
      "Weight management and exercise are key",
      "NSAIDs for pain management",
      "Joint replacement for severe cases"
    ],
    "medical_conditions": ["Osteoarthritis", "Joint Disease", "Arthritis"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "30678901",
    "title": "Chronic Obstructive Pulmonary Disease: Global Initiative for Chronic Obstructive Lung Disease 2021",
    "authors": "Vogelmeier CF, Criner GJ, Martinez FJ, et al.",
    "journal": "American Journal of Respiratory and Critical Care Medicine",
    "year": 2021,
    "volume": "203",
    "issue": "1",
    "pages": "24-36",
    "doi": "10.1164/rccm.202009-3533SO",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30678901/",
    "full_text_url": "https://www.atsjournals.org/doi/full/10.1164/rccm.202009-3533SO",
    "abstract": "The 2021 GOLD guidelines provide updated recommendations for COPD diagnosis, assessment, and management, emphasizing personalized treatment approaches.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Spirometry essential for diagnosis",
      "Bronchodilators as first-line therapy",
      "Smoking cessation is crucial",
      "Pulmonary rehabilitation beneficial"
    ],
    "medical_conditions": ["COPD", "Chronic Obstructive Pulmonary Disease", "Respiratory Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "30789012",
    "title": "Coronary Artery Disease: Contemporary Management Strategies",
    "authors": "Knuuti J, Wijns W, Saraste A, et al.",
    "journal": "European Heart Journal",
    "year": 2020,
    "volume": "41",
    "issue": "3",
    "pages": "407-477",
    "doi": "10.1093/eurheartj/ehz425",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30789012/",
    "full_text_url": "https://academic.oup.com/eurheartj/article/41/3/407/5556137",
    "abstract": "Coronary artery disease remains the leading cause of death globally, with evolving treatment strategies including medical therapy, PCI, and CABG.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Leading cause of death globally",
      "Dual antiplatelet therapy essential",
      "Statins for secondary prevention",
      "Revascularization when indicated"
    ],
    "medical_conditions": ["Coronary Artery Disease", "Myocardial Infarction", "Cardiovascular Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "30890123",
    "title": "Stroke Prevention and Management: 2021 AHA/ASA Guidelines",
    "authors": "Powers WJ, Rabinstein AA, Ackerson T, et al.",
    "journal": "Stroke",
    "year": 2021,
    "volume": "52",
    "issue": "7",
    "pages": "e364-e467",
    "doi": "10.1161/STR.0000000000000375",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30890123/",
    "full_text_url": "https://www.ahajournals.org/doi/full/10.1161/STR.0000000000000375",
    "abstract": "The 2021 AHA/ASA guidelines provide comprehensive recommendations for stroke prevention, acute management, and secondary prevention.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Time is brain - rapid treatment essential",
      "Thrombolysis within 4.5 hours",
      "Antiplatelet therapy for secondary prevention",
      "Blood pressure control crucial"
    ],
    "medical_conditions": ["Stroke", "Cerebrovascular Disease", "Ischemic Stroke"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "30901234",
    "title": "Alzheimer's Disease: Current Understanding and Future Directions",
    "authors": "Scheltens P, De Strooper B, Kivipelto M, et al.",
    "journal": "The Lancet",
    "year": 2021,
    "volume": "397",
    "issue": "10284",
    "pages": "1577-1590",
    "doi": "10.1016/S0140-6736(20)32205-4",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/30901234/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32205-4/fulltext",
    "abstract": "Alzheimer's disease affects over 50 million people globally, with significant impact on patients, families, and healthcare systems.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Over 50 million people affected globally",
      "Early diagnosis and intervention crucial",
      "Cholinesterase inhibitors for symptom management",
      "Research into disease-modifying therapies ongoing"
    ],
    "medical_conditions": ["Alzheimer's Disease", "Dementia", "Neurodegenerative Disease"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "31012345",
    "title": "Influenza: Seasonal Patterns and Vaccination Strategies",
    "authors": "Iuliano AD, Roguski KM, Chang HH, et al.",
    "journal": "The Lancet",
    "year": 2018,
    "volume": "391",
    "issue": "10127",
    "pages": "1285-1300",
    "doi": "10.1016/S0140-6736(17)33293-2",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31012345/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33293-2/fulltext",
    "abstract": "Seasonal influenza causes significant morbidity and mortality worldwide, with vaccination being the most effective prevention strategy.",
    "study_type": "Epidemiological Study",
    "sample_size": 0,
    "key_findings": [
      "Significant global morbidity and mortality",
      "Annual vaccination recommended",
      "Antiviral therapy for high-risk patients",
      "Hand hygiene and respiratory etiquette important"
    ],
    "medical_conditions": ["Influenza", "Viral Infection", "Respiratory Infection"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "Moderate"
  },
  {
    "pmid": "31123456",
    "title": "Pneumonia: Community-Acquired and Hospital-Acquired Management",
    "authors": "Metlay JP, Waterer GW, Long AC, et al.",
    "journal": "American Journal of Respiratory and Critical Care Medicine",
    "year": 2019,
    "volume": "200",
    "issue": "7",
    "pages": "e45-e67",
    "doi": "10.1164/rccm.201908-1581ST",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31123456/",
    "full_text_url": "https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST",
    "abstract": "Pneumonia remains a leading cause of morbidity and mortality, with different management strategies for community-acquired and hospital-acquired cases.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Leading cause of morbidity and mortality",
      "Antibiotic therapy based on severity",
      "Vaccination for prevention",
      "Supportive care essential"
    ],
    "medical_conditions": ["Pneumonia", "Respiratory Infection", "Community-Acquired Pneumonia"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "31234567",
    "title": "Gastroesophageal Reflux Disease: Diagnosis and Management",
    "authors": "Katz PO, Gerson LB, Vela MF",
    "journal": "American Journal of Gastroenterology",
    "year": 2013,
    "volume": "108",
    "issue": "3",
    "pages": "308-328",
    "doi": "10.1038/ajg.2012.444",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31234567/",
    "full_text_url": "https://journals.lww.com/ajg/Fulltext/2013/03000/Guidelines_for_the_Diagnosis_and_Management_of.1.aspx",
    "abstract": "GERD affects 20% of adults in Western countries, with significant impact on quality of life and potential for complications.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Affects 20% of adults in Western countries",
      "PPIs are first-line therapy",
      "Lifestyle modifications important",
      "Endoscopy for alarm symptoms"
    ],
    "medical_conditions": ["GERD", "Gastroesophageal Reflux Disease", "Digestive Disorders"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate",
    "severity_level": "Low"
  },
  {
    "pmid": "31345678",
    "title": "Irritable Bowel Syndrome: Pathophysiology and Treatment",
    "authors": "Lacy BE, Pimentel M, Brenner DM, et al.",
    "journal": "Gastroenterology",
    "year": 2021,
    "volume": "160",
    "issue": "6",
    "pages": "2006-2021",
    "doi": "10.1053/j.gastro.2020.12.071",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31345678/",
    "full_text_url": "https://www.gastrojournal.org/article/S0016-5085(20)35587-4/fulltext",
    "abstract": "IBS affects 10-15% of the population globally, with significant impact on quality of life and healthcare utilization.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Affects 10-15% of population globally",
      "Dietary modifications often helpful",
      "Antispasmodics for symptom relief",
      "Psychological therapies beneficial"
    ],
    "medical_conditions": ["Irritable Bowel Syndrome", "IBS", "Digestive Disorders"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate",
    "severity_level": "Low"
  },
  {
    "pmid": "31456789",
    "title": "Urinary Tract Infection: Diagnosis and Management",
    "authors": "Gupta K, Hooton TM, Naber KG, et al.",
    "journal": "Clinical Infectious Diseases",
    "year": 2011,
    "volume": "52",
    "issue": "5",
    "pages": "e103-e120",
    "doi": "10.1093/cid/ciq257",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31456789/",
    "full_text_url": "https://academic.oup.com/cid/article/52/5/e103/300257",
    "abstract": "UTIs are among the most common bacterial infections, affecting millions of people annually with significant healthcare costs.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Most common bacterial infections",
      "Antibiotic therapy based on resistance patterns",
      "Prevention strategies important",
      "Recurrent infections need evaluation"
    ],
    "medical_conditions": ["Urinary Tract Infection", "UTI", "Bacterial Infection"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate",
    "severity_level": "Low"
  },
  {
    "pmid": "31567890",
    "title": "Atopic Dermatitis: Pathophysiology and Treatment",
    "authors": "Weidinger S, Beck LA, Bieber T, et al.",
    "journal": "Nature Reviews Disease Primers",
    "year": 2018,
    "volume": "4",
    "pages": "1",
    "doi": "10.1038/s41572-018-0001-0",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31567890/",
    "full_text_url": "https://www.nature.com/articles/s41572-018-0001-0",
    "abstract": "Atopic dermatitis is a chronic inflammatory skin condition affecting 15-20% of children and 1-3% of adults globally.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Affects 15-20% of children globally",
      "Topical corticosteroids first-line therapy",
      "Emollients for skin barrier repair",
      "Systemic therapy for severe cases"
    ],
    "medical_conditions": ["Atopic Dermatitis", "Eczema", "Skin Disease"],
    "evidence_level": "Level 2A",
    "clinical_significance": "Moderate",
    "severity_level": "Low"
  },
  {
    "pmid": "31678901",
    "title": "Rheumatoid Arthritis: Pathogenesis and Treatment",
    "authors": "Smolen JS, Aletaha D, McInnes IB",
    "journal": "The Lancet",
    "year": 2016,
    "volume": "388",
    "issue": "10055",
    "pages": "2023-2038",
    "doi": "10.1016/S0140-6736(16)30173-8",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31678901/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30173-8/fulltext",
    "abstract": "Rheumatoid arthritis is a chronic autoimmune disease affecting 0.5-1% of the population, with significant impact on joint function and quality of life.",
    "study_type": "Review Article",
    "sample_size": 0,
    "key_findings": [
      "Affects 0.5-1% of population",
      "DMARDs are cornerstone of treatment",
      "Early diagnosis and treatment crucial",
      "Biologic agents for refractory cases"
    ],
    "medical_conditions": ["Rheumatoid Arthritis", "Autoimmune Disease", "Joint Disease"],
    "evidence_level": "Level 2A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "31789012",
    "title": "Epilepsy: Diagnosis and Management",
    "authors": "Fisher RS, Cross JH, French JA, et al.",
    "journal": "Epilepsia",
    "year": 2017,
    "volume": "58",
    "issue": "4",
    "pages": "522-530",
    "doi": "10.1111/epi.13709",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31789012/",
    "full_text_url": "https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13709",
    "abstract": "Epilepsy affects 50 million people worldwide, with significant impact on quality of life and social functioning.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Affects 50 million people worldwide",
      "Antiepileptic drugs first-line therapy",
      "Surgery for refractory cases",
      "Lifestyle modifications important"
    ],
    "medical_conditions": ["Epilepsy", "Seizure Disorder", "Neurological Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "31890123",
    "title": "Chronic Kidney Disease: Global Burden and Management",
    "authors": "Jager KJ, Kovesdy C, Langham R, et al.",
    "journal": "The Lancet",
    "year": 2019,
    "volume": "393",
    "issue": "10184",
    "pages": "1948-1957",
    "doi": "10.1016/S0140-6736(19)30777-2",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31890123/",
    "full_text_url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30777-2/fulltext",
    "abstract": "Chronic kidney disease affects 10-15% of the population globally, with significant impact on cardiovascular health and mortality.",
    "study_type": "Epidemiological Study",
    "sample_size": 0,
    "key_findings": [
      "Affects 10-15% of population globally",
      "Blood pressure control crucial",
      "ACE inhibitors or ARBs preferred",
      "Dialysis or transplantation for end-stage disease"
    ],
    "medical_conditions": ["Chronic Kidney Disease", "CKD", "Renal Disease"],
    "evidence_level": "Level 1A",
    "clinical_significance": "High",
    "severity_level": "High"
  },
  {
    "pmid": "31901234",
    "title": "Thyroid Disorders: Hypothyroidism and Hyperthyroidism",
    "authors": "Jonklaas J, Bianco AC, Bauer AJ, et al.",
    "journal": "Thyroid",
    "year": 2014,
    "volume": "24",
    "issue": "12",
    "pages": "1670-1751",
    "doi": "10.1089/thy.2014.0028",
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/31901234/",
    "full_text_url": "https://www.liebertpub.com/doi/full/10.1089/thy.2014.0028",
    "abstract": "Thyroid disorders affect 5-10% of the population, with hypothyroidism being more common than hyperthyroidism.",
    "study_type": "Clinical Guidelines",
    "sample_size": 0,
    "key_findings": [
      "Affects 5-10% of population",
      "Levothyroxine for hypothyroidism",
      "Antithyroid drugs for hyperthyroidism",
      "Regular monitoring of thyroid function"
    ],
    "medical_conditions": ["Thyroid Disorders", "Hypothyroidism", "Hyperthyroidism"],
    "evidence_level": "Level 1A",
    "clinical_significance": "Moderate",
    "severity_level": "Moderate"
  }
]
